Edesa Biotech Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Edesa Biotech Stock Summary

Edesa Biotech competes with Cue Biopharma, Tff Pharmaceuticals, Eliem Therapeutics, Inhibrx, and Molecular Partners. Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada. Edesa Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.

Edesa Biotech Key Financial Ratios

Edesa Biotech Key Balance Sheet Accounts

Edesa Biotech Key Income Statement Accounts

Edesa Biotech Key Cash Accounts

Edesa Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Edesa Biotech's current stock value. Our valuation model uses many indicators to compare Edesa Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Edesa Biotech competition to find correlations between indicators driving Edesa Biotech's intrinsic value. More Info.Edesa Biotech is rated # 3 in return on equity category among its peers. It is rated # 5 in return on asset category among its peers . At present, Edesa Biotech's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Edesa Biotech's earnings, one of the primary drivers of an investment's value.

Edesa Biotech Systematic Risk

Today, most investors in Edesa Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Edesa Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Edesa Biotech growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Edesa Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Edesa Biotech. We use our internally-developed statistical techniques to arrive at the intrinsic value of Edesa Biotech based on widely used predictive technical indicators. In general, we focus on analyzing Edesa Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Edesa Biotech's daily price indicators and compare them against related drivers.

When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.